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Background: We aimed to measure SARS-CoV-2 seroprevalence in a 
cohort of healthcare workers (HCWs) during the first UK wave of the 
COVID-19 pandemic, explore risk factors associated with infection, 
and investigate the impact of antibody titres on assay sensitivity. 
Methods: HCWs at Sheffield Teaching Hospitals NHS Foundation Trust 
were prospectively enrolled and sampled at two time points. SARS-
CoV-2 antibodies were tested using an in-house assay for IgG and IgA 
reactivity against Spike and Nucleoprotein (sensitivity 99·47%, 
specificity 99·56%). Data were analysed using three statistical models: 
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a seroprevalence model, an antibody kinetics model, and a 
heterogeneous sensitivity model. 
Results: As of 12th June 2020, 24·4% (n=311/1275) of HCWs were 
seropositive. Of these, 39·2% (n=122/311) were asymptomatic. The 
highest adjusted seroprevalence was measured in HCWs on the Acute 
Medical Unit (41·1%, 95% CrI 30·0–52·9) and in Physiotherapists and 
Occupational Therapists (39·2%, 95% CrI 24·4–56·5). Older age groups 
showed overall higher median antibody titres. Further modelling 
suggests that, for a serological assay with an overall sensitivity of 80%, 
antibody titres may be markedly affected by differences in age, with 
sensitivity estimates of 89% in those over 60 years but 61% in those ≤30 years. 
Conclusions:  HCWs in acute medical units working closely with 
COVID-19 patients were at highest risk of infection, though whether 
these are infections acquired from patients or other staff is unknown. 
Current serological assays may underestimate seroprevalence in 
younger age groups if validated using sera from older and/or more 
symptomatic individuals.
Keywords 
Seroprevalence; antibody; Healthcare Worker; SARS-CoV-2; COVID; 
modelling; age; risk
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Introduction
Healthcare workers (HCWs) are at increased risk of 
COVID-191,2. The true number of HCWs exposed to 
SARS-CoV-2 to-date is unknown, particularly during the 
early stages of the pandemic. Initial methods to estimate 
HCW exposure included extrapolation from work absenteeism 
rates, and are unlikely to be reliable3. Confirmation by 
molecular testing increased the accuracy of case detection, 
although access to nucleic acid amplification testing (NAAT) 
was limited during the early stages of the pandemic in the UK4. 
Detection of exposure by antibody seroconversion may provide 
a more accurate estimate of risk in HCW populations, can be 
performed at large scale, and is less affected by symptom- 
activated testing pathways5–8.
To enable the accurate interpretation of seroprevalence 
readouts, detailed characterisation of antibody evolution relative 
to the sampling time-frame, immunoglobulin isotype, antigenic 
target and assay performance is required9–14, Many antibody 
assays have been evaluated using samples from hospitalised 
patients; it is unclear how these assays perform with the lower 
antibody levels found in those with more mild or asymptomatic 
SARS-CoV-2 infection10,12. Furthermore, while antibody lev-
els to some coronaviruses are higher in older individuals, it is 
unclear whether this results from a higher risk or exposure to the 
virus, greater antigenic load or boosting of antibodies from 
previous seasonal coronavirus infections15–19. This may also lead 
to age-specific differences in antibody assay sensitivity, which 
could be a significant confounder in population seroprevalence 
studies.
In this study we measure SARS-CoV-2 seroprevalence in 
HCWs at Sheffield Teaching Hospitals NHS Foundation Trust 
(STH), following the first wave of the pandemic in the UK. 
We model the kinetics of the evolving antibody response, the 




STH offers secondary- and tertiary-level care across four sites 
in South Yorkshire, UK, and has 1,669 inpatient beds and 
18,500 employees20. The first patient with confirmed COVID-19 
was admitted to STH on 23 February 2020; the first wave of 
the UK pandemic occurred between March 2020 and June 2020.
Testing of symptomatic staff for SARS-CoV-2 by NAAT was 
introduced on 17 March 2020. On the same day, Public Health 
England (PHE) de-escalated the recommendations for the per-
sonal protective equipment (PPE) required by HCWs caring for 
inpatients with suspected or confirmed COVID-19 from 
‘Level 3 Airborne’ to ‘Level 2 Droplet’ for routine care21. 
Subsequently, the requirement for universal ‘Level 2 Droplet’ 
PPE for all inpatient and outpatient care began on 08 April 2020. 
Local STH policy was changed on 15 June 2020 to mandate 
staff use surgical face masks while on hospital premises.
Recruitment and consent
From 13–18 May 2020, all contactable STH staff (n=17,757) 
were invited to take part in the COVID-19 Humoral ImmunE 
RespOnses in front-line HCWs (HERO) study by email and 
intranet alert. To engage staff in areas with limited communi-
cations access, additional recruitment posters and face-to-face 
enrolment sessions were used.
Following an electronic informed consent process, participants 
provided self-reported data on-line on age, gender, ethnic-
ity, job role, and pandemic working environment (‘COVID-19 
zones’)21. Details of any possible or confirmed prior COVID-19 
illnesses occurring since 01 February 2020 was also collected. 
These were categorised as: i), diagnosed with COVID-19 and 
confirmed by NAAT, ii), clinically diagnosed with COVID-19 
but NAAT not performed, and iii), self-reported symptoms 
only21. Together, we defined these three groups as “symptomatic”, 
as asymptomatic testing was only introduced after the study 
recruitment period. Those reporting no illness between 
01 February 2020 to the date of recruitment were defined as 
“asymptomatic”. All that had enrolled were emailed times of 
phlebotomy appointments, and were invited to attend on a 
first come first served basis for the first visit, and then invited 
by email to book a specific appointment slot to attend for their 
second visit after four weeks +/- 7 days. An 8.5ml serum 
sample was taken at each visit to outpatient phlebotomy services for 
serological testing.
SARS-CoV-2 serology
Serum samples were tested for IgG and IgA reactivity 
to two SARS-CoV-2 proteins using an in-house ELISA: 
the full-length extracellular domain (amino acids 14-1213) 
of Spike glycoprotein, including a replacement of the furin 
cleavage site R684-R689 by a single alanine residue and replace-
ment of K986-V987 by PP, produced in mammalian cells; 
and full-length untagged Nucleocapsid protein (NCP) produced 
in E. coli (Uniprot ID P0DTC9 (NCAP_SARS2))22–24. High 
binding microtitre plates (Immulon 4HBX; Thermo Scien-
tific, 6405) were coated overnight with proteins diluted in 
phosphate buffered saline, washed with 0·05% PBS-Tween, 
and blocked for one hour with 200 µL/well casein buffer. 
Following optimisation, sample dilutions used were 1:200 for 
the IgG assay or 1:100 for the IgA assay21. Plates were emptied 
and 100 µL/well of sample or control loaded. After two hours 
incubation, plates were washed and loaded with goat anti-human 
IgG-HRP conjugate (Invitrogen, 62-8420) at 1:500, or goat 
anti-human IgA-HRP conjugate (Invitrogen, 11594230) at 1:1000, 
for one hour. Plates were washed and developed for 10 minutes 
with 100 µL/well TMB substrate (KPL, 5120-0074). Develop-
ment was stopped with 100 µL/well HCl Stop solution (KPL, 
5150-0021), and absorbance read at 450nm. All steps were 
performed at room temperature.
A calibration curve of sera pooled from convalescent 
SARS-CoV-2 NAAT-confirmed patients with high antibody 
titres for both spike and NCP was included on plates to allow 
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quantification of antibody concentrations. The calibration 
curve was generated by serially diluting in 1·75× steps from a 
starting concentration of 1:200 for the IgG assay or 1:100 for 
the serum IgA assay. When the WHO International Standard 
for anti-SARS-CoV-2 immunoglobulin (NIBSC, 20/136) later 
became available, the calibration curve was run in parallel for 
the IgG assay21. Data for the IgG assay are therefore given in 
WHO antibody units, whereas IgA assay data are given in 
arbitrary antibody units.
Sample size
To meet the primary objective of measuring the 
SARS-CoV-2 IgG seroprevalence, we calculated a sample size 
of 1,000 HCWs would provide +/-1·4% precision based on 
a seroprevalence estimate that ~4% of the UK population 
may have been infected by April 2020, with a two-sided 95% 
confidence interval (with n=753, Binomial exact 95%CI has been 
estimated to be 2·7-5·6%)25.
Statistical modelling
We considered three statistical models, i) a seroprevalence 
model, ii) an antibody kinetics model, and iii) a heterogeneous 
sensitivity model. For the seroprevalence model, we used the 
serostatus of all participants at first blood draw in a sensitivity- 
and specificity-adjusted Bayesian multilevel logistic regression 
model. Using seropositivity as the binary response variable, 
we considered three different model subtypes with varying 
primary exposures; job location, contact with COVID-19 
patients, and job type21. In addition, we fitted a symptomatic 
prevalence model, where the data used were seropositive per-
sons only, and the binary response variable was asymptomatic 
or symptomatic infection.
For the antibody kinetics model, we included samples from 
seropositive individuals in a Bayesian multilevel linear regres-
sion model in two parts: i) using log2 antibody units (logAU) at 
the first blood draw as the response variable and ii) using 
the change in antibody titre at the follow up bleed (median 
28 days) as the response variable. Age, ethnicity, gender and 
symptom severity (asymptomatic or symptomatic) were used as 
covariates and each model was run separately for four different 
antibody-antigen combinations; Spike-IgG, NCP-IgG, Spike-IgA, 
NCP-IgA. The time until seroreversion was calculated for 
each covariate group and antibody-antigen interactions by 
i) sampling a starting titre value and a rate of decline from the 
two models, and then ii) calculating the time until the minimum 
observed antibody value was reached for that antibody-antigen 
interaction, assuming a continuous rate of decrease.
In our heterogeneous sensitivity and specificity model, we 
explored how estimates derived from our assay validation data-
set generalise to covariate groups, e.g. participant age. To model 
the generalisability of these performance measures, we compared 
the seropositivity classification of our study dataset using our 
in-house antibody assay, with the predicted seropositivity clas-
sification from hypothetical assays with a quoted sensitivity and 
specificity. Our model considers the different distribution 
of the A
450
 values in the assay validation and HERO study 
datasets to model how reliably quoted performance measures 
generalise. Using the assay validation dataset, we estimated the 
A
450
 cut-off value for a range of chosen sensitivity values, and 
then used this A
450
 cut-off to classify seropositivity in the 
study dataset. We then estimated the implied sensitivity on 
the HERO dataset by comparing seropositivity classification 
based on the estimated A
450
 cut-off value, with the seropositivity 
classification from our in-house assay (which for ease of 
comparison, we assume represents the maximum possible 
sensitivity and specificity (i.e. 100%) in this model). This 
framework allowed us to estimate the hypothetical perform-
ance of serological assays reported in the literature on our HERO 
dataset, along with co-variate specific sensitivity.
All analysis was performed in R version 4.0.2 and cmdstanr 
version 0.2.0. An R package containing all the analysis in 
this study is available at https://doi.org/10.5281/zenodo.5215671.
Regulatory review
Following internal scientific review, local R&D (5 May 2020 
ref: STH21394) and HRA and Health and Care Research 
Wales (HCRW) approval were given (29 April 2020 
ref: 20/HRA/2180, IRAS ID: 283461). Anonymised serum 
samples from hospitalised COVID-19 patients and serum 
collected prior to 2017 during routine clinical care were used for 
assay validation with approval from STH R&D office.
Results
Serology assay development
The assay validation dataset26 consisted of serum from 190 
SARS-CoV-2 NAAT-confirmed cases (52 hospitalised patients 
and 138 healthcare workers with mild infections sampled 
between 14 and 120 days from NAAT positivity), and 
675 patients sampled prior to 2017 (Extended data: Table S1). 
Thresholds for defining reactivity to spike (A
450
 0·1750) or 
NCP (A
450
 0·1905) were set to optimise the sensitivity of each 
assay. Given the IDSA guidance for ensuring a specificity of 
≥99·5% in assays used for SARS-CoV-2 seroprevalence studies, 
specificity was enhanced by defining a SARS-CoV-2 seropositive 
sample as one where both spike and NCP were reactive27. This 
resulted in a sensitivity of 99·47% (95% confidence inter-
val (CI) 97·10% - 99·99%) and specificity of 99·56% (95% CI 
98·71% - 99·91%) for our IgG assay (Extended data: 
Figure S1). Rapid waning of IgA responses following 
SARS-CoV-2 infection complicated defining positive and 
negative samples based on the convalescent sera we used for 
assay validation. We also observed more background reactivity 
for IgA compared to IgG in pre-pandemic samples. We 
therefore opted to use our spike and NCP IgA ELISA purely for 
comparing IgA levels in individuals classified as seropositive 
in our IgG assay (Extended data: Figure S2). Antibody units 
at each given dilution of the calibration curve are shown in 
Table S2 (Extended data).
Registration and study visits
1478 STH staff consented to take part between 13 May and 
5 June 2020 (Extended data: Figure S3). Of these, 1277 attended 
for a first visit (V1) between 15 May 2020 and 12 June 2020. 
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As two samples were contaminated in transit, we obtained a valid 
serostatus for 1275 samples. 1174 attended for a second visit 
(V2) between 15 June and 10 July 2020 (Extended data: 
Figures S3 and S4).
Demographics, job role, work locations, and 
environment
The majority of participants were female (n=1008/1275, 
79·1%) and most described their ethnicity as white (n=1130/1275, 
88·6%, Table 1). Nurses (433/1275, 33·9%), doctors (232/1275, 
18·2%), health care assistants (163/1275, 12·8%), and 
domestic services staff (136/1275, 10·7%) constituted the larg-
est proportion of job roles. Almost half (593/1275, 46·5%) of 
HCWs worked in parts of the hospital managing acute 
COVID-19 admissions including the Emergency Department 
(ED), Acute Medical Unit (AMU), Critical Care, and inpatient 
medical wards (respiratory, geriatric care, infectious diseases). 
Participants reported working in areas with the highest level of 
COVID-19 patient contact (red zones), either most days 
(n=423/1275, 33·2%) or occasionally (n=305/1275, 23·9%).
Unadjusted seroprevalence
Analysis of V1 samples revealed that 24·4% (n=311/1275) 
of HCWs were seropositive by 12 June 2020 (Table 1). 
Of these, 39·2% (n=122/311) did not report a prior illness con-
sistent with COVID-19. The second blood draw occurred 
a median of 28 days following the first visit (IQR 27-31) and 
1166 had a valid V2 serology result (Extended data: Figure S3). 
Comparison of serology data from both visits demonstrated 
that 16 out of 964 participants had seroconverted and 9 out 
of 311 participants seroreverted (i.e. loss of reactivity against 
either spike (A
450 




The overall adjusted seroprevalence in the cohort was 23·1% 
(95% CrI 14·1–33·3), but varied across job type, job location and 
COVID-19 zone (Figure 1; Extended data: Tables S3 to S7). 
A relatively high seroprevalence was seen in occupational and 
physiotherapists (39·2%, 95% CrI 24·4–56·5), and low 
seroprevalence in allied medical staff (9·2%, 95% CrI 1·4–21·3). 
Between wards, there was higher seroprevalence in the 












both V1 and 
V2 (% of 
recruited)
Seroincident 
cases (% of 
seronegative 
at V1)




103 26 (25·2) 13 (50·0) 90 (87·4) 1 (1·2)
Acute Medical Unit 
(AMU)
83 38 (45·8) 17 (44·4) 66 (79·5) 0 (0·0)
Critical Care 100 18 (18·0) 7 (38·9) 95 (95·0) 0 (0·0)
Geriatric Care 23 3 (13·0) 1 (33·3) 22 (95·7) 1 (5·0)
Infectious Disease 
Ward
139 26 (18·7) 11 (42·3) 121 (87·1) 7 (6·2)
Other 664 157 (23·6) 56 (35·7) 621 (93·5) 2 (0·3)
Respiratory Geriatric 
Ward
92 27 (29·3) 10 (37·0) 85 (92·4) 2 (3·1)
Respiratory Ward 58 13 (22·4) 5 (38·5) 54 (93·1) 2 (4·4)
Job role
Admin 127 26 (20·5) 12 (46·2) 118 (92·9) 1 (0·9)
Allied medical1 38 0 (0·0) — 37 (97·4) 0 (0·0)
Domestic services 136 39 (28·7) 24 (61·5) 127 (93·4) 4 (4·1)
Healthcare 
assistants
163 39 (23·9) 21 (53·8) 140 (85·9) 3 (2·4)
Doctors 232 52 (22·4) 18 (34·6) 211 (90·9) 0 (0·0)
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both V1 and 
V2 (% of 
recruited)
Seroincident 
cases (% of 
seronegative 
at V1)
Nurses 433 116 (26·7) 34 (29·3) 391 (90·3) 7 (2·2)
Other 31 5 (16·1) 2 (40·0) 29 (93·5) 0 (0·0)
Pharmacists 35 8 (22·8) 5 (62·5) 33 (94·3) 1 (3·7)
Occupational and 
physiotherapists
33 15 (45·5) 3 (20·0) 33 (100·0) 0 (0·0)
Radiographers 42 9 (21·4) 2 (22·2) 42 (100·0) 0 (0·0)
COVID-19 zone2 
1 (lowest COVID-19 
contact)
104 22 (21·2) 10 (54·5) 96 (92·3) 1 (1·2)
2 248 50 (20·2) 27 (46·0) 232 (93·5) 0 (0·0)
3 41 7 (17·1) 6 (14·3) 39 (95·1) 1 (2·9)
4 153 35 (22·9) 24 (31·4) 142 (92·8) 1 (0·8)
5 305 69 (22·6) 46 (33·3) 280 (91·8) 3 (1·3)
6 (highest COVID-19 
contact)
423 128 (30·3) 76 (40·6) 376 (88·9) 10 (3·4)
Age (years)
<30 267 67 (25·1) 32 (47·8) 236 (88·4) 6 (3·0)
30–39 306 69 (22·5) 22 (31·8) 279 (91·2) 5 (2·1)
40–49 314 72 (22·9) 29 (40·2) 293 (93·3) 2 (0·8)
50–59 314 76 (24·2) 28 (36·8) 288 (91·7) 1 (0·4)
60+ 74 27 (36·5) 11 (40·7) 70 (94·6) 2 (4·3)
Ethnicity
White 1130 281 (24·9) 108 (38·4) 1035 (91·6) 15 (1·8)
Black/Black British 33 6 (18·2) 3 (50·0) 30 (90·9) 0 (0·0)
Asian/Asian British 76 17 (22·4) 7 (41·2) 70 (92·1) 1 (1·7)
Other 33 7 (21·2) 4 (57·1) 30 (90·9) 0 (0·0)
Gender3 
Female 1008 253 (24·1) 105 (41·5) 922 (91·5) 14 (1·9)
Male 265 58 (21·9) 17 (29·3) 242 (91·3) 2 (0·9)
1Allied Medical includes Speech and Language Therapists, Cardiac Physiologists, Dental Hygienists, Dietitians, ECG technicians, 
Orthotists, Podiatrists, Rehabilitation assistants
2COVID-19 Zones are defined in extended data21 
3Participants were able to define their gender as non-binary, transgender or could choose not to disclose
AMU (41·1%, 95% CrI 30·0–52·9) compared to other wards. 
Across COVID-19 zones, working in the areas with the high-
est degree of COVID-19 patient contact (zone 6) was associated 
with a slightly higher seroprevalence of 28·6% (95% CrI 
24·0–33·5) compared to the other five groups (Figure 1). 
The adjusted proportion of asymptomatic cases was 38·9% (95% 
CrI 23·6–57·3) (Extended data: Figure S5). The proportion of 
asymptomatic cases remained relatively consistent across all 
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Figure 1. Model-predicted seroprevalence estimates for three different models (A-C), adjusted and unadjusted with covariates. 
Black stars represent point values from the data. The point and whiskers represent the mean value and 95% CrI of the posterior distribution. 
The three models differed by their primary exposure, Model A used COVID-19 zones (1 refers to lowest COVID-19 contact and 6 refers to 
highest COVID-19 contact21), Model B the job role, and Model C the job location. Each model was evaluated either unadjusted (primary 
exposure only) or adjusted (primary exposure with age, gender, and ethnicity).
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covariates except for job type, where it ranged from 21·4% for 
occupational and physiotherapists up to 61·5% for domestic 
services staff (Extended data: Figure S5).
Antibody kinetics model
Differences in antibody concentration between samples 
were calculated for four different antibody-antigen interac-
tions (spike-IgG, NCP-IgG, spike-IgA, NCP-IgA). Though there 
was a positive correlation between Spike-IgG and NCP-IgG 
across all samples (R2= 0·53), the correlations between serum 
IgG and IgA were much weaker (R2 between 0·17 and 0·3) 
(Extended data: Figure S6).
For both serum IgG and IgA, older age groups showed higher 
antibody titres (Figure 2); E.g., the median log2 titre of 
spike-IgG in those ≤30 years was 6·6 (95% CrI 6·2–7·0), and 
at 60+ years was 7·1 (95% CrI 6·6–7·8), while spike-IgA 
titre in those ≤30 years was 6·8 (95% CrI 6·3–7·3), and at 
60+ years was 7·6 (95% CrI 7·0–8·3). Symptomatic cases 
showed similar titres compared to asymptomatic cases across 
IgG and IgA-serum measures. The reduction in antibody titre 
at the second blood draw was less in the spike-IgG (mean -0·15 
(95% CrI -0·25– -0·06)) compared to NCP-IgG (mean -0·49 
(95% CrI -0·58– -0·540)) and Spike-IgA/NCP-IgA. These 
estimated rates of decline remained consistent across all 
covariate groups studied. Consequently, the estimated time 
until seroreversion for seropositive samples from symptomatic 
participants was around 100 weeks for the spike-IgG, and 
52 weeks for NCP-IgG and IgA serum measures (Figure 2). 
When considering seropositive samples from symptomatic 
participants, there was little difference in the decrease in 
antibody levels as time post-symptom onset increased (Extended 
data: Figure S7).
Heterogeneous sensitivity model
The heterogeneous sensitivity model demonstrates that using 
varying A
450
 cut-offs (corresponding to varying sensitivity val-
ues) to categorise seropositivity in the HERO dataset will result 
in a lower sensitivity than that defined using our assay valida-
tion dataset (Figure 3a). The model also shows that there is no 
difference in implied sensitivity between using spike or NCP 
as the antigenic target in the ELISA assay.
The relationship between the A
450
 cut-off value and the 
sensitivity and specificity for the assay validation datasets for each 
antigen were plotted with the associated ROC curves (Extended 
data: Figures S8 and S9). We hypothesised that the higher 
A
450
 values seen in older adults suggest that some commercially 
available serological assays may have a higher sensitivity 
in detecting COVID-19 antibodies in older age groups com-
pared with younger age groups. We therefore used our model to 
estimate age-specific implied sensitivity for assays of different 
sensitivity profiles in estimating seroprevalence in our HERO 
dataset. We found that the sensitivity of a serological assay 
decreases with age due to the higher antibody titres seen 
in older people, with a clearer trend in an NCP-based assay 
compared to a spike-based assay (Figure 3b). Assuming a 
theoretical assay validation set sample sensitivity of 80% for 
the NCP protein, the resulting median implied sensitivity 
for age groups <30, 30–39, 40–49, 50–59, and 60+ years was 
61%, 77%, 70%, 85%, and 89% respectively.
Discussion
We found a high SARS-CoV-2 seroprevalence in HCWs at 
a large UK hospital trust compared to national seropreva-
lence estimates, following the first pandemic wave in the UK28. 
In addition, we identified important risk factors associated 
with occupational exposure to COVID-19, and described a 
significant association between age and the likelihood of a 
positive serological result which has important implications 
for the validation of SARS-CoV-2 antibody assays and the 
hitherto interpretation of population-level COVID-19 serology 
data.
Over 20% of HCWs at STH had evidence of SARS-CoV-2 
infection within just over 100 days of the first confirmed 
COVID-19 patient being admitted to our NHS trust. This high 
proportion over a short space of time is likely representative 
of the much higher exposure to SARS-CoV-2 infection 
among certain subpopulations of the workforce that we tested. 
Although data from other settings and countries suggested 
infection risk in HCWs is similar to community exposure, 
this seroprevalence is much higher than estimated serop-
ositivity in the UK population at a similar time (6·0%, 95 
CrI 5·8–6·1 in July 2020)28,29.
Our data show that HCWs working in AMUs are at significantly 
higher risk of infection with SARS-CoV-2, with seropositivity 
rates above that of other wards, consistent with other UK 
studies5,6,30. EDs face a similar patient turnover yet have 
lower HCW seroprevalence rates in both ours and previous 
reports5,6,30,31. Although some patient factors may increase HCW 
risk of infection on AMU compared to ED (cohort bays, 
longer stays, more fomites e.g. bedside tables, chairs), more 
frequent interactions and therefore transmission between 
HCWs may also play a significant additional role. In the 
event of a further wave or outbreak, infection prevention and 
control (IPC) interventions to reduce risk in these areas could 
include targeted IPC training and auditing (particularly of 
PPE use and break areas), serial staff testing, pop-up isolation 
units in bay areas and optimising staff-to-patient ratios. At the 
other end of the spectrum, we and others have found that 
HCWs in critical care units have some of the lowest seroposi-
tivity rates, which likely reflects ‘Level 3 Airborne’ PPE use in 
Critical Care units from an early point in the pandemic and the 
increased availability of negative pressure rooms5,6,8,30,31.
Occupational and physiotherapists (OT/PT) had the highest 
rates of seroprevalence across all of the job roles included in our 
cohort (45.5%), which is consistent with some other UK 
studies6,32. OT/PT work involves prolonged close contact with 
patients in addition to PT performing chest physiotherapy 
and open suctioning of the respiratory tract. In addition, 
OT/PT work across multiple inpatient and outpatient areas in 
our Trust, which could increase risk of transmission from both 
patients and other HCWs.
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Figure 2. Outputs from the antibody kinetics model for four antibody-antigen interactions (spike-IgG, NCP-IgG, spike-IgA, 
and NCP-IgA). The IgG measures are in the WHO standard universal log2 antibody units, whereas the IgA measures are in log2(AU) units 
scaled relative to the values in the study. The dots show the median and the line segments show the 95% credible interval of the posterior 
distributions. Top panel shows the log2(AU) at the first bleed across four different covariates (Age group, ethnicity, gender, and disease 
severity). Middle panels show the change in log2(AU) after 30 days. The bottom panels show the time until seroreversion in weeks. Asymp 
(asymptomatic participants), Symp (symptomatic participants) PSO (post symptom onset).
Increasing age was associated with seropositivity, with 
over a third of our HCWs aged >60 testing seropositive, and with 
higher antibody titres. We demonstrate that the sensitivity of 
a serological assay increases with increasing age due to the 
higher antibody titres seen in older people, and with a clearer 
trend in NCP- compared to spike-based assays. Consistent with 
other studies, we also found that NCP-IgG is likely to wane 
more quickly than Spike-IgG. Depending on the sampling time 
frame relative to pandemic wave, therefore, serological testing 
based on NCP-IgG alone may therefore underestimate 
seroprevalence i.e. potential exposure to infection. As two of 
the major commercial SARS-CoV-2 antibody assays (Roche 
Elecsys and Abbott SARS-CoV-2 IgG) were validated with 
patient sera collected from those with more severe disease 
early on in the pandemic (i.e. those who presented to health 
services). Previous studies clearly demonstrate that patients 
with more severe COVID-19 have higher antibody titres and it 
would be reasonable to assume these cases were likely to 
also be older in age33–36. Our findings suggest that using such 
samples collected from severely symptomatic older patients 
for the purposes of assay calibration may result in an assay with 
lower or insufficient sensitivity when applied to less symptomatic 
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Figure 3. (a) Sensitivity of the assay validation dataset against the implied sensitivity of the HERO dataset for spike and nucleoprotein. 
(b) Sensitivity of the assay validation dataset against the implied age-specific sensitivity in the HERO dataset for spike and nucleoprotein. 
Black line and ribbon shows median and 95% CrI for the posterior distributions respectively.
or younger (often community) populations. With increasing 
vaccine coverage, use of spike IgG to determine seroprevalence 
also becomes more problematic when distinguishing whether 
an individual is seropositive from vaccination or previous 
infection. Assays which combine antibody responses to membrane 
protein with NCP antibodies may overcome these challenges37,38.
We note the limitations of our study, which include a poten-
tial for selection bias due to participants self-enrolling for 
convenience, rather than using systematic sampling. Reassur-
ingly, our seroprevalence rates are similar to those seen in other 
UK based seroprevalence studies5,32. In addition, we recognise 
that our cohort has relatively low numbers of HCWs from 
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minority ethnic backgrounds (~10%), compared to the Sheffield 
general population (19%)39.
With the ongoing global devastation caused by the COVID-19 
pandemic and its lasting effect on healthcare services, 
understanding the risk factors leading to HCW exposure is 
paramount to ensuring the continuity of effective and safe 
patient care. Our real-world data suggest that NHS HCWs face 
high levels of exposure to SARS-CoV-2, plus highlights 
locations and job roles at greatest risk during the first wave of 
the pandemic. Population seroprevalence data can help guide 
decision makers on risk management. Using assays that have 
been validated using serum samples from a broad population, 
combined with antibody kinetic modelling and/or with age-
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